Treace Medical Concepts, Inc. TMCI R2K
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 14.5% over 5 years.
CONS
- Earnings shrank at -12.6% CAGR over 5 years.
- Trading 55.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 82 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TMCI Treace Medical Concepts, Inc. R2K | 3.46 | - | $224.46M | - | -33.56% | -66.88% | 14.46% | -12.60% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.26M | 7.74M | 14.27M | 18.71M | 20.65M | 21.62M | 29.05M | 29.97M | 33.05M | 42.20M | 41.95M | 40.76M | 51.11M | 44.45M | 45.09M | 52.57M | 47.39M | 50.21M | 62.52M | 47.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.68M | 9.63M | 10.51M | 12.12M | 9.79M |
| Gross Profit | 8.87M | 5.65M | 11.36M | 15.38M | 16.71M | 17.37M | 23.92M | 24.68M | 26.96M | 34.16M | 34.28M | 32.76M | 40.98M | 35.67M | 36.13M | 41.89M | 37.75M | 39.71M | 50.40M | 37.41M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 57.48M | 54.73M | 55.38M | 56.32M | 54.57M |
| Operating Income | -1.20M | -1.52M | -63.00K | -1.40M | -4.05M | -5.46M | -8.10M | -11.93M | -11.32M | -13.78M | -13.05M | -17.82M | -18.97M | -21.38M | -15.13M | -15.58M | -16.97M | -15.68M | -5.92M | -17.17M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -12.15M | -13.50M | -12.17M | -5.24M | -15.49M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.31M | 1.32M | 1.34M | 1.35M | 1.57M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.92M | -17.40M | -16.29M | -9.39M | -17.96M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.61M | -1.97M | -2.65M | -2.43M | -5.08M | -6.42M | -9.04M | -17.23M | -12.13M | -13.45M | -12.27M | -17.52M | -18.68M | -21.21M | -15.36M | -15.92M | -17.40M | -16.29M | -9.39M | -17.96M |
| Diluted EPS | - | - | - | - | -0.10 | -0.12 | -0.16 | -0.31 | -0.22 | -0.23 | -0.20 | -0.28 | -0.30 | -0.34 | -0.25 | -0.25 | -0.28 | -0.26 | -0.15 | -0.28 |
| R&D Expense | 1.43M | 982.00K | 1.51M | 1.87M | 2.42M | 2.54M | 3.05M | 2.98M | 3.80M | 3.41M | 3.53M | 4.35M | 5.26M | 5.16M | 4.96M | 5.56M | 5.50M | 4.68M | - | 4.62M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 39.42M | 57.37M | - | 141.84M | 187.12M | 209.36M | 212.69M |
| Cost of Revenue | - | - | - | 25.53M | 35.18M | 41.09M | 42.94M |
| Gross Profit | 31.79M | 44.90M | - | 116.31M | 151.94M | 168.26M | 169.75M |
| Operating Expenses | - | - | - | 151.15M | 203.37M | 223.95M | 223.91M |
| Operating Income | -3.54M | 855.00K | - | -34.84M | -51.43M | -55.69M | -54.15M |
| EBITDA | - | - | - | -36.28M | -39.01M | -42.07M | -43.06M |
| Interest Expense | - | - | - | 4.40M | 5.17M | 5.26M | 5.32M |
| Pretax Income | - | - | - | -42.81M | -49.53M | -55.74M | -59.00M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -4.26M | -3.67M | - | -42.81M | -49.53M | -55.74M | -59.00M |
| Diluted EPS | - | -0.12 | -0.43 | -0.77 | -0.81 | -0.90 | - |
| R&D Expense | 5.07M | 5.85M | 10.20M | 13.58M | 15.44M | 20.59M | 20.28M |
Compounded Sales Growth
| 5 Years: | 14.46% |
| 1 Year: | -10.20% |
Compounded Profit Growth
| 5 Years: | -12.60% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -39.72% |
| 6 Months: | +11.97% |
| 3 Months: | +86.02% |
| 1 Month: | +94.38% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 41.81M | - | 159.02M | 251.91M | 217.09M | 190.58M |
| Current Assets | - | - | - | - | 133.40M | 198.36M | 161.40M | 132.05M |
| Cash & Equivalents | 1.28M | 12.14M | 18.08M | - | 19.47M | 12.98M | 11.35M | 10.71M |
| Inventory | - | - | - | - | 19.33M | 29.25M | 39.26M | 36.03M |
| Receivables | - | - | - | - | 29.20M | 38.06M | 40.80M | 42.16M |
| Total Liabilities | - | - | 41.03M | - | 98.50M | 113.97M | 104.20M | 103.25M |
| Current Liabilities | - | - | 11.60M | - | 30.25M | 45.03M | 34.92M | 30.64M |
| Long Term Debt | - | - | 29.19M | - | 52.71M | 53.01M | 53.31M | 55.58M |
| Total Debt | - | - | - | - | 68.59M | 70.30M | 69.65M | 71.86M |
| Total Equity | 5.95M | 3.16M | 776.00K | - | 60.53M | 137.94M | 112.89M | 87.33M |
| Shares Outstanding | - | - | - | - | 55.63M | 61.75M | 62.39M | 64.03M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.67M | -4.49M | - | -30.65M | -34.58M | -37.17M | -15.97M |
| Investing Cash Flow | -1.21M | -1.07M | - | -76.52M | -81.30M | 35.38M | 13.25M |
| Financing Cash Flow | 19.74M | 11.50M | - | 20.81M | 109.38M | 160.00K | 2.08M |
| Capital Expenditure | -1.21M | -1.07M | - | -14.84M | -11.46M | -11.59M | -13.52M |
| Free Cash Flow | -8.88M | -5.56M | - | -45.49M | -46.03M | -48.76M | -29.49M |
| Net Change in Cash | - | - | - | -86.36M | -6.49M | -1.63M | -642.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | 80.6% | 78.3% | - | 82.0% | 81.2% | 80.4% | 79.8% |
| Operating Margin % | -9.0% | 1.5% | - | -24.6% | -27.5% | -26.6% | -25.5% |
| Net Margin % | -10.8% | -6.4% | - | -30.2% | -26.5% | -26.6% | -27.7% |
| ROE % | -134.9% | -472.7% | - | -70.7% | -35.9% | -49.4% | -67.6% |
| ROCE % | - | 2.8% | - | -27.1% | -24.9% | -30.6% | -33.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Armistice Capital, LLC | 9.81% | 6.36M | $22.02M |
| 2 | Gagnon Securities, LLC | 8.02% | 5.20M | $18.00M |
| 3 | Blackrock Inc. | 5.15% | 3.34M | $11.56M |
| 4 | Bank of America Corporation | 4.95% | 3.21M | $11.12M |
| 5 | CIBC Private Wealth Group, LLC | 2.28% | 1.48M | $5.12M |
| 6 | Vanguard Capital Management LLC | 2.25% | 1.46M | $5.06M |
| 7 | State Street Corporation | 1.90% | 1.24M | $4.27M |
| 8 | CIBC Bancorp USA Inc. | 1.88% | 1.22M | $4.22M |
| 9 | Millennium Management Llc | 1.77% | 1.15M | $3.97M |
| 10 | AQR Capital Management, LLC | 1.64% | 1.06M | $3.67M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TMCI